Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus

Tingting Zhao, Qian Xing, Xiao‐Juan Yang, Xiaofeng Yao, Ying Ba, Haicheng Zhou, Dan LiuClinical 2020 · DOI

TL;DR

This case report details a rare instance of a 31-year-old male presenting with central diabetes insipidus (CDI) and portopulmonary hypertension (POPH) secondary to idiopathic portal hypertension (IPH). The study highlights the complex interplay between these conditions and the potential therapeutic role of vasopressin analogs, offering a unique perspective on managing this challenging clinical scenario.

What Problem Does This Paper Address?

The paper addresses the diagnostic and therapeutic challenges posed by the co-occurrence of central diabetes insipidus (CDI) and portopulmonary hypertension (POPH) in a patient with underlying idiopathic portal hypertension (IPH). While IPH is a known risk factor for POPH, and CDI is a distinct endocrine disorder, their simultaneous presentation is exceptionally rare. The authors aim to elucidate the pathophysiology, diagnostic approaches, and treatment strategies for this complex constellation of diseases, particularly focusing on the role of vasopressin in their management. Understanding this interplay is crucial for clinicians encountering patients with unexplained polyuria and pulmonary hypertension, especially those with a history of liver disease or related complications.

Methods

This paper is a case report, meaning the primary "method" is the detailed clinical observation and management of a single patient. The diagnostic process involved:

  • Physical Examination and Laboratory Tests: Standard assessments for fluid balance, urine concentration (urine osmolality, specific gravity), and serum osmolality were performed.
  • Imaging: MRI was used to investigate the pituitary gland for microadenoma, and chest X-ray was employed to assess for pulmonary lesions. Ultrasonic cardiography was utilized to estimate pulmonary artery pressure.
  • Water Deprivation Test and Desmopressin (DDAVP) Trial: These are considered the "gold standard" for diagnosing CDI. The water deprivation test assesses the body's ability to concentrate urine, followed by the administration of DDAVP to observe the urine's response.
  • Pulmonary Artery CTA: This imaging technique was used to rule out pulmonary embolism as a cause of pulmonary hypertension.
  • Liver Biopsy: Performed to assess liver pathology and rule out other causes of portal hypertension.
  • Therapeutic Intervention: The patient was treated with oral DDAVP acetate for CDI and monitored for its effects on both CDI and POPH.

The novelty lies not in a new methodology but in the application of established diagnostic tools to a rare clinical presentation and the subsequent observation of therapeutic responses.

Datasets

Not discussed in the paper. This is a case report focusing on a single patient's clinical journey.

Key Insights and Ideas

  • Complex Interplay of Vasopressin: The case highlights how vasopressin, or its synthetic analog DDAVP, can influence multiple systems. While DDAVP is standard for CDI, its effect on POPH is less understood and potentially beneficial.
  • DDAVP's Dual Role: The report suggests that DDAVP, while treating CDI, might also have a positive impact on POPH. This is attributed to DDAVP's potential vasorelaxant properties on pulmonary arteries, possibly mediated by endothelial nitric oxide synthase activation.
  • Pathogenesis Uncertainty: The exact pathogenesis of this patient's combined conditions remains unclear. The authors note that while IPH can lead to increased AVP secretion, this patient presented with AVP deficiency (CDI).
  • Diagnostic Challenges: Differentiating CDI from other causes of polyuria and ruling out other etiologies for POPH requires a systematic approach, especially in the presence of multiple co-existing conditions.
  • Importance of Comprehensive Evaluation: The case underscores the need for thorough investigation when patients present with seemingly unrelated symptoms, as underlying connections can exist.

Key Results

  • Confirmation of CDI: The patient was definitively diagnosed with central diabetes insipidus based on a water deprivation test and a positive response to desmopressin.
  • Confirmation of POPH: Ultrasonic cardiography revealed severe pulmonary hypertension with an estimated systolic pulmonary arterial pressure (sPAP) of 85 mm Hg.
  • Therapeutic Efficacy of DDAVP: Oral DDAVP acetate effectively managed the patient's polyuria and polydipsia, reducing 24-hour urine output to 6-7 L (at 0.05 mg four times daily) and further to 4-5 L (at 0.2-0.25 mg per day).
  • POPH Stability with DDAVP: Importantly, the patient's condition remained stable for 8 months while on DDAVP, suggesting it did not exacerbate his pulmonary hypertension. Polyuria and polydipsia returned upon discontinuation of DDAVP.

Limitations and Future Work

Limitations:

  • Single Case Report: The findings are based on a single patient, limiting generalizability.
  • Unclear Pathogenesis: The underlying cause for the co-occurrence of CDI and IPH/POPH in this patient is not fully elucidated.
  • Limited Long-Term Follow-up: While an 8-month follow-up is reported, longer-term data on the sustained effects of DDAVP on both CDI and POPH would be beneficial.

Future Work:

  • Further Investigation into Pathogenesis: The authors emphasize the need for further research to understand the role of arginine vasopressin (AVP) in the pathogenesis of such complex cases.
  • Studies on Similar Patients: They encourage studies of similar patients to identify potential underlying mechanisms and develop better treatment strategies.
  • Understanding DDAVP's Effect on POPH: More research is needed to confirm and elucidate the mechanisms behind DDAVP's potential beneficial effects on pulmonary hypertension.

Summary updated

Abstract

We discuss the pathophysiology, diagnosis, differential diagnosis, and therapy of a case with central diabetes insipidus, idiopathic portal hypertension, and portopulmonary hypertension. This report reviews how vasopressin affects those diseases.
BibTeX
@inproceedings{zhao2020portopulmonary,
  author = {Tingting Zhao and Qian Xing and Xiao‐Juan Yang and Xiaofeng Yao and Ying Ba and Haicheng Zhou and Dan Liu},
  title = {{Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus}},
  booktitle = {Clinical},
  year = {2020},
  doi = {10.1002/ccr3.2675},
}
Figure